secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2025-05-07T23:59:59+00:00
Accession:  0001683168-25-003237
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phio Pharmaceuticals reports complete pathologic response in 2 of 3 patients in third cohort of INTASYL PH-762 trial
--------------------------------------------------------------------------------

- 2 of 3 cSCC patients in Cohort 3 achieved 100% tumor clearance; third patient had <50% clearance.
- Across 10 patients in Cohorts 1-3: 4 complete responses, 1 near complete (>90%), 1 partial (>50%).
- No dose-limiting toxicities or clinically relevant adverse effects reported; PH-762 well tolerated.
- Fourth cohort enrolling; Phio expects to complete trial enrollment in Q3 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000168316825003237/0001683168-25-003237-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000168316825003237/phio_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-25-003237

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer